Luxoft Holding, Inc Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

Luxoft Holding, Inc announced today the closing of its initial public offering of 4,705,880 Class A ordinary shares at $17.00 per Class A ordinary share, which includes the exercise in full by the underwriters of their option to purchase up to 613,810 additional Class A ordinary shares. 2,046,035 of the Class A ordinary shares were offered by Luxoft, and another 2,659,845 Class A ordinary shares, which includes the over-allotment, were offered by its parent, IBS Group Holding Limited. Luxoft’s ordinary shares are listed on the New York Stock Exchange under the trading symbol “LXFT”.

Timberland Appoints New President

Timo Schmidt- Eisenhart becomes President of Timberland EMEA, the newly formed top position under the VF Corporation management. The promotion is effective immediately. He will be reporting directly to Karl Heinz Salzburger, Vice President VF Corporation and Group President International.

Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced data from a post-hoc analysis examining progression-free survival (PFS) following treatment with ADCETRIS® (brentuximab vedotin) versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma (HL) post-autologous stem cell transplant (ASCT) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma (ICML) being held June 19–22, 2013 in Lugano, Switzerland.

Carestream Health’s Medical Imaging System to Journey Across Antarctica

A CARESTREAM DRX-Transportable System is on its way to Antarctica as part of the latest expedition led by veteran polar explorer, Sir Ranulph Fiennes. One of the last remaining polar challenges, the expedition will attempt to cross Antarctica in winter—the coldest journey on earth—an astounding passage of nearly 4,000 kilometres, mostly in complete darkness and in temperatures as low as -90°C.

Toys“R”Us, Inc. Strengthens Global E-Commerce Presence with Launch of Dedicated Web Store in China, Mobile Shopping Capabilities Introduced in Additional International Markets

Toys“R”Us, Inc. today announced it has strengthened its global e-commerce capabilities with the launch of a dedicated web store, Toysrus.com.cn, in China. The addition of this site represents a significant step in the company’s plans to grow its presence with physical stores and online operations in Asia. The company has also announced the development of mobile-optimized sites and apps in 11 markets around the world, including Australia, Canada, France, Germany, Japan, Spain, and the U.K. In the coming months, it will introduce the same capabilities in Portugal, Austria and Switzerland, as well as the Netherlands, where it does not currently have a store presence.

MEDMIX Systems AG Announces Twin-Syringe Biomaterial Delivery System with Low Pressure Air-Assisted Spray Nozzle and Laparoscopic Tip

MEDMIX Systems AG has developed a delivery system for the use with standard single syringes to handle multi-component biomaterials such as tissue-adhesives, fibrin-glues for tissue sealing and materials for wound treatment, as well as stem-cell or PRP preparation. This biomaterial delivery system will be featured at 13th EFORT Congress, Berlin, Germany at MEDMIX booth #15.1/36 from May 23 – 25, 2012

Plexxikon Announces European Approval of Zelboraf® for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf® (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. The cobas 4800 BRAF V600 Mutation Test, a companion diagnostic used to identify patients with the BRAF mutation, is CE marked and commercially available in Europe. Zelboraf is designed to selectively inhibit the BRAF mutation that occurs in about half of all cases of melanoma.

Accenture Study: Majority of Companies Say They Must Rethink Their Capabilities To Secure Growth in Emerging Markets

A majority of global business leaders say their companies are looking to high growth emerging economies to fuel their next stage of growth, but do not believe they have the necessary capabilities to compete in these markets, a new Accenture (NYSE: ACN) study finds. According to a survey of 588 business leaders in 85 countries, 80 percent say their company’s primary focus for growth is on emerging economies, but 73 percent believe they must accelerate their efforts to build sufficient market share in these high-growth markets, or may, in fact, be too late to do so.

Gillette Fields Team for the London 2012 Olympic Games

Gillette, a P&G brand, today introduced a team of 24 world-class athletes from 18 countries that will represent the world’s leading male grooming brand at the 2012 Olympic Games in London. The athletes include Roger Federer of Switzerland, Ryan Lochte of the United States, Lin Dan of China, Emmanuel Ginobili of Argentina and Sir Chris Hoy of Great Britain. Each of these athletes will participate in activities to help inspire and encourage future generations to achieve greatness through great starts in athletics – and in life.